A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-11-14
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-08 (study day 8); relationship: N
mild
assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-11-15 (study day 350); relationship: Y
mild
assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-12-11 (study day 376); relationship: not assessed
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-04-25 (study day 512); relationship: not assessed
Data queries
No data queries.